Management of Recurrent Depressive Disorder, Anxiety, and Insomnia in a Patient With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia Receiving Dasatinib Therapy: A Case Report

Psychiatric symptoms, including depression, anxiety, and insomnia, are common among patients with cancer and may complicate the management of oncological disease.This report presents a case of a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL) receiving dasatinib treatment who experienced a recurrence of depressive symptoms accompanied by insomnia, severe anxiety, and fatigue.The case highlights the challenges of psychopharmacological management in the context of potential drug-drug interactions associated with concomitant oncological treatment.A 55-year-old woman was admitted to a psychiatric inpatient unit because of worsening depressive symptoms, insomnia, severe anxiety, and fatigue.Pharmacological treatment was adjusted during hospitalisation, with treatment decisions influenced by potential pharmacokinetic interactions, QT interval prolongation risk, and the patient's concerns regarding medication changes.In addition to pharmacological treatment, the patient participated in a multidisciplinary psychiatric rehabilitation programme.During hospitalisation, her overall clinical condition gradually improved, with improvements in mood, anxiety, and sleep.Individualised psychopharmacological treatment, careful consideration of potential drug-drug interactions, and collaboration between psychiatrists and oncologists are important in the management of psychiatric comorbidity in patients with ALL.Patient engagement in treatment decisions may further support a treatment approach tailored to individual needs.